

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart

NCT06701669

Status	RECRUITING
Phase	Phase 2
Sponsor	PPD Development, LP
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (1)

- ARDS Severity of moderate or severe based on PaO₂/FiO₂ or SpO₂/FiO₂ assessment at the time of randomization.

Exclusion (1)

- Participant has a known allergy or known hypersensitivity to paridiprubart or its excipients, including polysorbate 80

Locations (36 total)

University of Alabama Hospital, Birmingham, Alabama, United States
Community Regional Medical Center, Fresno, California, United States
Long Beach Memorial Medical Center, Long Beach, California, United States
... and 33 more locations